Thank you, Sherry. [Technical Difficulty] all for joining us for our 2020 half year release of results for MDxHealth. With me today is Ron Kalfus, Chief Financial Officer. Well, none of us could have anticipated how the first half of 2020 would play out, the MDx team has been and will continue to focus on the following. Number one, maintaining our laboratory operations to the highest standards, while continuing to support the needs of our clinicians and, most importantly, patients. Number two, discipline and focus in building on the progress we have made in sales, revenue cycle management and capital allocation. And number three, our employee wellbeing through rigorous and process based adherence to safety. It should be noted and as documented, that screening for all cancers is down materially in the U.S. over the past six months. While prostate cancer is no exception, we expect that as all important patient access and flow returns, we will be well positioned to capitalize on the recovery. However, even amidst the challenges presented by this environment, I am very confident in the fundamental drivers of our business that provided the basis for our optimistic outlook at the beginning of the year. While our guidance has been appropriately suspended, pending better visibility to the rebound in patient visits and procedures in the US, we believe our results underscore our confidence and provide clear evidence of our restructured focus on commercial and operating execution. Confirm MDx test volume and revenue, while down year-over-year, clearly exceeded trends in the oncology diagnostic sector. And continued demand through the first half of 2020 is additional evidence that our clinical pathway is beginning to be cemented into our Confirm MDx user base. Our revenue cycle management execution is also clearly showing improved and sustainable results, even amidst the pandemic. Again, discipline, focus and leadership in this group, coupled with expanded coverage, will continue to drive leverage in our cash collections and associated operating efficiency. Live test volume was affected by comparisons to some non-recurring volume in 2019, focus on ConfirmMDx in the back half of 2019, as well as to greater degree by the pandemic is expected, and mirrors more closely the industry trends related to screening and patient access limitations. That said, we are very encouraged by the recent inclusion of SelectMDx into the National Comprehensive Cancer Network, also known as NCCN guidelines. This recognition of our SelectMDx test signifies the highest standard of acknowledgment for clinical utility in the diagnosis and treatment of prostate cancer. We expect to see our volumes continue to normalize and return to growth as we go forward. Although the timing of the recovery will be subject to the dynamics well documented and characterized in the U.S. diagnostics market. We are already seen some elastic response to the previous easing of lifetime restrictions in the U.S. and all this vary by geography and will likely continue to fluctuate and/or moderate through our acute period of the pandemic. We are confident that our customer base remains well intact, and that our volumes will recover likely led by ConfirmMDx with SelectMDx to follow. Please be clear that in the interim, we remain connected to and encouraged by the engagement with our current, as well as pipeline customers that we are building through the efforts of our sales team. While it is too early to characterize, we believe that there is a buildup of physician and patient interactions, and the easing of restrictions, patient and access, and the associated return of flow through our customer’s clinical pathway will accelerate and contribute to future growth. I will comment further on our view going forward, but first, let me turn the call over to Ron to review our financial results for the first half. Ron?
